COR2ED Medical Education
@cor2ed.com
COR2ED develops high-quality Independent Medical Education programmes for HCPs globally.
Visit our website: https://cor2ed.com/
Read the Community Guidelines: https://t.co/KZbQi7TR4U
#MedEd #IME #MedicalEducation
Visit our website: https://cor2ed.com/
Read the Community Guidelines: https://t.co/KZbQi7TR4U
#MedEd #IME #MedicalEducation
Closing the Gap in HPP Care 2025
webapp.spotme.com/login/alexio...
📅 2 & 4 December | Live sessions
Initiated and funded by Alexion, AstraZeneca Rare Disease and brought to you in collaboration with COR2ED Medical Affairs. Intended for healthcare professionals only. M/GL/Med HPP/0096 | Nov 2025
webapp.spotme.com/login/alexio...
📅 2 & 4 December | Live sessions
Initiated and funded by Alexion, AstraZeneca Rare Disease and brought to you in collaboration with COR2ED Medical Affairs. Intended for healthcare professionals only. M/GL/Med HPP/0096 | Nov 2025
November 17, 2025 at 9:03 AM
Closing the Gap in HPP Care 2025
webapp.spotme.com/login/alexio...
📅 2 & 4 December | Live sessions
Initiated and funded by Alexion, AstraZeneca Rare Disease and brought to you in collaboration with COR2ED Medical Affairs. Intended for healthcare professionals only. M/GL/Med HPP/0096 | Nov 2025
webapp.spotme.com/login/alexio...
📅 2 & 4 December | Live sessions
Initiated and funded by Alexion, AstraZeneca Rare Disease and brought to you in collaboration with COR2ED Medical Affairs. Intended for healthcare professionals only. M/GL/Med HPP/0096 | Nov 2025
Today is #WorldHPPDay
#Hypophosphatasia (HPP) is a #RareDisease that can impact working, connecting, and living independently
In the video (GL/UNB-H/0096), Suzanne & Amy share their HPP stories 📺
This material has been initiated and funded by Alexion Pharmaceuticals. 10/2025 GL/UNB-H/0095
#Hypophosphatasia (HPP) is a #RareDisease that can impact working, connecting, and living independently
In the video (GL/UNB-H/0096), Suzanne & Amy share their HPP stories 📺
This material has been initiated and funded by Alexion Pharmaceuticals. 10/2025 GL/UNB-H/0095
October 30, 2025 at 9:19 AM
Today is #WorldHPPDay
#Hypophosphatasia (HPP) is a #RareDisease that can impact working, connecting, and living independently
In the video (GL/UNB-H/0096), Suzanne & Amy share their HPP stories 📺
This material has been initiated and funded by Alexion Pharmaceuticals. 10/2025 GL/UNB-H/0095
#Hypophosphatasia (HPP) is a #RareDisease that can impact working, connecting, and living independently
In the video (GL/UNB-H/0096), Suzanne & Amy share their HPP stories 📺
This material has been initiated and funded by Alexion Pharmaceuticals. 10/2025 GL/UNB-H/0095
Rethinking HPP (hypophosphatasia)
➡️ HPP is an inherited disorder that can impact a patient’s ability to work, connect, and live independently
Watch the video (GL/UNB-H/0087) for key facts 📺
This material has been initiated and funded by Alexion Pharmaceuticals. 10/2025 GL/UNB-H/0091
#RareDiseases
➡️ HPP is an inherited disorder that can impact a patient’s ability to work, connect, and live independently
Watch the video (GL/UNB-H/0087) for key facts 📺
This material has been initiated and funded by Alexion Pharmaceuticals. 10/2025 GL/UNB-H/0091
#RareDiseases
October 23, 2025 at 10:40 AM
Rethinking HPP (hypophosphatasia)
➡️ HPP is an inherited disorder that can impact a patient’s ability to work, connect, and live independently
Watch the video (GL/UNB-H/0087) for key facts 📺
This material has been initiated and funded by Alexion Pharmaceuticals. 10/2025 GL/UNB-H/0091
#RareDiseases
➡️ HPP is an inherited disorder that can impact a patient’s ability to work, connect, and live independently
Watch the video (GL/UNB-H/0087) for key facts 📺
This material has been initiated and funded by Alexion Pharmaceuticals. 10/2025 GL/UNB-H/0091
#RareDiseases
Reposted by COR2ED Medical Education
Colleagues at #ESMO25 , Join our Collaborators at COR2ED and Dr. Lizzy Smyth straight from Berlin 👉 cor2ed.com/esmo-2025/up...
Dr Smyth will review key studies including MATTERHORN, LEAP-014, and SKYSCRAPER-07 — and discuss whether these results could change clinical practice.
Dr Smyth will review key studies including MATTERHORN, LEAP-014, and SKYSCRAPER-07 — and discuss whether these results could change clinical practice.
October 19, 2025 at 9:00 AM
Colleagues at #ESMO25 , Join our Collaborators at COR2ED and Dr. Lizzy Smyth straight from Berlin 👉 cor2ed.com/esmo-2025/up...
Dr Smyth will review key studies including MATTERHORN, LEAP-014, and SKYSCRAPER-07 — and discuss whether these results could change clinical practice.
Dr Smyth will review key studies including MATTERHORN, LEAP-014, and SKYSCRAPER-07 — and discuss whether these results could change clinical practice.
Reposted by COR2ED Medical Education
Colleagues at #ESMO25
Dr Herbert Loong shares his perspectives on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at ESMO 2025. Go to the COR2ED website to watch his video update and download the accompanying slides
cor2ed.com/esmo-2025/on...
Dr Herbert Loong shares his perspectives on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at ESMO 2025. Go to the COR2ED website to watch his video update and download the accompanying slides
cor2ed.com/esmo-2025/on...
October 20, 2025 at 9:30 AM
Colleagues at #ESMO25
Dr Herbert Loong shares his perspectives on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at ESMO 2025. Go to the COR2ED website to watch his video update and download the accompanying slides
cor2ed.com/esmo-2025/on...
Dr Herbert Loong shares his perspectives on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) presented at ESMO 2025. Go to the COR2ED website to watch his video update and download the accompanying slides
cor2ed.com/esmo-2025/on...
Reposted by COR2ED Medical Education
Prof. Viktor Grünwald shares his renal cell carcinoma highlights from ESMO 2025 as he reviews the latest data from the LenCabo, KEYMAKER-U03 and CLEAR studies. He also discusses staging of disease with the radiolabelled peptide ([68Ga]Ga-DPI-4452).
cor2ed.com/esmo-2025/re...
cor2ed.com/esmo-2025/re...
October 21, 2025 at 8:30 AM
Prof. Viktor Grünwald shares his renal cell carcinoma highlights from ESMO 2025 as he reviews the latest data from the LenCabo, KEYMAKER-U03 and CLEAR studies. He also discusses staging of disease with the radiolabelled peptide ([68Ga]Ga-DPI-4452).
cor2ed.com/esmo-2025/re...
cor2ed.com/esmo-2025/re...
Reposted by COR2ED Medical Education
Dear Colleagues, Our Collaborators at COR2ED Invite you to watch Highlights from #ESMO25
WATCH HERE 👉 cor2ed.com/esmo-2025/br...
Straight from Berlin, Experts share their views on new data on #BreastCancer & #GynOnc
NOW ON DEMAND
WATCH HERE 👉 cor2ed.com/esmo-2025/br...
Straight from Berlin, Experts share their views on new data on #BreastCancer & #GynOnc
NOW ON DEMAND
October 23, 2025 at 10:02 AM
Dear Colleagues, Our Collaborators at COR2ED Invite you to watch Highlights from #ESMO25
WATCH HERE 👉 cor2ed.com/esmo-2025/br...
Straight from Berlin, Experts share their views on new data on #BreastCancer & #GynOnc
NOW ON DEMAND
WATCH HERE 👉 cor2ed.com/esmo-2025/br...
Straight from Berlin, Experts share their views on new data on #BreastCancer & #GynOnc
NOW ON DEMAND
How can new clinical trials in radioligand therapy impact clinical practice in #NET treatment strategies?
Find out in this new #MedEd video from medical experts
cor2ed.com/net-connect/...
Supported by an Independent Educational Grant from ITM
@nanets.bsky.social #MedSky #medicaleducation 📷
Find out in this new #MedEd video from medical experts
cor2ed.com/net-connect/...
Supported by an Independent Educational Grant from ITM
@nanets.bsky.social #MedSky #medicaleducation 📷
October 6, 2025 at 3:00 PM
How can new clinical trials in radioligand therapy impact clinical practice in #NET treatment strategies?
Find out in this new #MedEd video from medical experts
cor2ed.com/net-connect/...
Supported by an Independent Educational Grant from ITM
@nanets.bsky.social #MedSky #medicaleducation 📷
Find out in this new #MedEd video from medical experts
cor2ed.com/net-connect/...
Supported by an Independent Educational Grant from ITM
@nanets.bsky.social #MedSky #medicaleducation 📷
📢 New #dermatology micro learning!
Improving acne vulgaris with multimodal treatment strategies
>> cor2ed.com/dermatology-...
📺 4-min video, downloadable flashcard & slides, and accredited assessment
Supported by an Independent Educational Grant from Glenmark Pharmaceuticals
#MedSky
Improving acne vulgaris with multimodal treatment strategies
>> cor2ed.com/dermatology-...
📺 4-min video, downloadable flashcard & slides, and accredited assessment
Supported by an Independent Educational Grant from Glenmark Pharmaceuticals
#MedSky
Improving acne vulgaris with multimodal treatment strategies | COR2ED
In this micro learning module, developed by experts Prof. Alison Layton and Prof. Dr Falk Ochsendorf, you will explore multimodal treatment strategies for
cor2ed.com
August 11, 2025 at 1:29 PM
📢 New #dermatology micro learning!
Improving acne vulgaris with multimodal treatment strategies
>> cor2ed.com/dermatology-...
📺 4-min video, downloadable flashcard & slides, and accredited assessment
Supported by an Independent Educational Grant from Glenmark Pharmaceuticals
#MedSky
Improving acne vulgaris with multimodal treatment strategies
>> cor2ed.com/dermatology-...
📺 4-min video, downloadable flashcard & slides, and accredited assessment
Supported by an Independent Educational Grant from Glenmark Pharmaceuticals
#MedSky
2025 is anticipated to be the year with the highest number of phase 3 ADC trials read outs in breast oncology, with impact for all breast cancer subtypes.
Here’s 8 ADC breast cancer trials expected to reshape practice in 2025:
Here’s 8 ADC breast cancer trials expected to reshape practice in 2025:
August 11, 2025 at 1:20 PM
🔎 Expert insights on recent #BreastCancer data
Dr Paolo Tarantino discusses data from SERENA-6, ASCENT-04/KEYNOTE-D19 & DESTINY-Breast09 studies presented at #ASCO25
Watch his video & see more ASCO updates
▶️ cor2ed.com/n-connect/pr...
Supported by COR2ED #MedEd #MedSky @ptarantinomd.bsky.social
Dr Paolo Tarantino discusses data from SERENA-6, ASCENT-04/KEYNOTE-D19 & DESTINY-Breast09 studies presented at #ASCO25
Watch his video & see more ASCO updates
▶️ cor2ed.com/n-connect/pr...
Supported by COR2ED #MedEd #MedSky @ptarantinomd.bsky.social
July 8, 2025 at 10:25 AM
🔎 Expert insights on recent #BreastCancer data
Dr Paolo Tarantino discusses data from SERENA-6, ASCENT-04/KEYNOTE-D19 & DESTINY-Breast09 studies presented at #ASCO25
Watch his video & see more ASCO updates
▶️ cor2ed.com/n-connect/pr...
Supported by COR2ED #MedEd #MedSky @ptarantinomd.bsky.social
Dr Paolo Tarantino discusses data from SERENA-6, ASCENT-04/KEYNOTE-D19 & DESTINY-Breast09 studies presented at #ASCO25
Watch his video & see more ASCO updates
▶️ cor2ed.com/n-connect/pr...
Supported by COR2ED #MedEd #MedSky @ptarantinomd.bsky.social
🚨 Best practices in managing early relapsed/refractory multiple myeloma
3-part video series with expert insights & downloadable slide sets
⬇️
cor2ed.com/lymphoma-mye...
Supported by an Independent Educational Grant from Menarini Stemline Oncology
#MedSky #MedEd #RRMM
3-part video series with expert insights & downloadable slide sets
⬇️
cor2ed.com/lymphoma-mye...
Supported by an Independent Educational Grant from Menarini Stemline Oncology
#MedSky #MedEd #RRMM
Early relapsed/refractory multiple myeloma (RRMM): best practices in management | COR2ED
cor2ed.com
July 3, 2025 at 10:16 AM
🚨 Best practices in managing early relapsed/refractory multiple myeloma
3-part video series with expert insights & downloadable slide sets
⬇️
cor2ed.com/lymphoma-mye...
Supported by an Independent Educational Grant from Menarini Stemline Oncology
#MedSky #MedEd #RRMM
3-part video series with expert insights & downloadable slide sets
⬇️
cor2ed.com/lymphoma-mye...
Supported by an Independent Educational Grant from Menarini Stemline Oncology
#MedSky #MedEd #RRMM
➡️Tx strategies for pts w/ advanced #HCC who are ineligible for #immunotherapy or with progression on #IO
👉 cor2ed.com/hcc-connect/...
Endorsed by @digestivecancerseu.bsky.social @bluefaeryliver.bsky.social @aasldnews.bsky.social @europeliver.bsky.social
Supported by an IME Grant from Bayer #meded
👉 cor2ed.com/hcc-connect/...
Endorsed by @digestivecancerseu.bsky.social @bluefaeryliver.bsky.social @aasldnews.bsky.social @europeliver.bsky.social
Supported by an IME Grant from Bayer #meded
Navigating advanced HCC: treatment strategies beyond immunotherapy (IO) | COR2ED
In this micro learning, developed by experts Assoc. Prof. Lorenza Rimassa and Dr Amit Singal, you will learn about treatment strategies for patients who
cor2ed.com
July 2, 2025 at 6:51 PM
➡️Tx strategies for pts w/ advanced #HCC who are ineligible for #immunotherapy or with progression on #IO
👉 cor2ed.com/hcc-connect/...
Endorsed by @digestivecancerseu.bsky.social @bluefaeryliver.bsky.social @aasldnews.bsky.social @europeliver.bsky.social
Supported by an IME Grant from Bayer #meded
👉 cor2ed.com/hcc-connect/...
Endorsed by @digestivecancerseu.bsky.social @bluefaeryliver.bsky.social @aasldnews.bsky.social @europeliver.bsky.social
Supported by an IME Grant from Bayer #meded
Congratulations to the newly elected ESMO Directors & Nomination Committee members!
A special mention to:
👏 GI CONNECT's Dr @lizzysmyth.bsky.social
👏 PRECISION ONCOLOGY CONNECT's Prof. Ulrik Lassen
👏 Prof. Rachel Riechelmann, who has collaborated with NET CONNECT
#MedicalEducation #ESMO #MedSky
A special mention to:
👏 GI CONNECT's Dr @lizzysmyth.bsky.social
👏 PRECISION ONCOLOGY CONNECT's Prof. Ulrik Lassen
👏 Prof. Rachel Riechelmann, who has collaborated with NET CONNECT
#MedicalEducation #ESMO #MedSky
ESMO announces the 2025 election results for the Director positions and the Nomination Committee.
Thank you to all #ESMOMembers who voted and contributed to shaping the Society’s future direction.
📢 Curious to see who was elected?
🔗 Read the full announcement: buff.ly/F1beK90
Thank you to all #ESMOMembers who voted and contributed to shaping the Society’s future direction.
📢 Curious to see who was elected?
🔗 Read the full announcement: buff.ly/F1beK90
June 18, 2025 at 7:57 AM
Congratulations to the newly elected ESMO Directors & Nomination Committee members!
A special mention to:
👏 GI CONNECT's Dr @lizzysmyth.bsky.social
👏 PRECISION ONCOLOGY CONNECT's Prof. Ulrik Lassen
👏 Prof. Rachel Riechelmann, who has collaborated with NET CONNECT
#MedicalEducation #ESMO #MedSky
A special mention to:
👏 GI CONNECT's Dr @lizzysmyth.bsky.social
👏 PRECISION ONCOLOGY CONNECT's Prof. Ulrik Lassen
👏 Prof. Rachel Riechelmann, who has collaborated with NET CONNECT
#MedicalEducation #ESMO #MedSky
📹 Watch the video > cor2ed.com/n-connect/pr...
Video: The evolution of our understanding that led us to rethink #hypophosphatasia (HPP) 💡
w/ Dr Chad Deal
Programme initiated & funded by Alexion Pharmaceuticals. Intended for healthcare professionals only. GL/UNB-H/0074
#MedEd #MedSky #EULAR2025
Video: The evolution of our understanding that led us to rethink #hypophosphatasia (HPP) 💡
w/ Dr Chad Deal
Programme initiated & funded by Alexion Pharmaceuticals. Intended for healthcare professionals only. GL/UNB-H/0074
#MedEd #MedSky #EULAR2025
Rethinking hypophosphatasia (HPP) diagnosis and disease burden | COR2ED
cor2ed.com
June 12, 2025 at 4:21 PM
📹 Watch the video > cor2ed.com/n-connect/pr...
Video: The evolution of our understanding that led us to rethink #hypophosphatasia (HPP) 💡
w/ Dr Chad Deal
Programme initiated & funded by Alexion Pharmaceuticals. Intended for healthcare professionals only. GL/UNB-H/0074
#MedEd #MedSky #EULAR2025
Video: The evolution of our understanding that led us to rethink #hypophosphatasia (HPP) 💡
w/ Dr Chad Deal
Programme initiated & funded by Alexion Pharmaceuticals. Intended for healthcare professionals only. GL/UNB-H/0074
#MedEd #MedSky #EULAR2025
📣Update from #ASCO25
Expert insights on the latest data: cor2ed.com/n-connect/pr...
#NSCLC #ProstateCancer #GICancer #BreastCancer #OvarianCancer #CervicalCancer
NSCLC update supported by an Independent Educational Grant from Bayer.Other updates supported by COR2ED
#MedEd @lizzysmyth.bsky.social
Expert insights on the latest data: cor2ed.com/n-connect/pr...
#NSCLC #ProstateCancer #GICancer #BreastCancer #OvarianCancer #CervicalCancer
NSCLC update supported by an Independent Educational Grant from Bayer.Other updates supported by COR2ED
#MedEd @lizzysmyth.bsky.social
Highlights from ASCO 2025 | COR2ED
cor2ed.com
June 12, 2025 at 12:25 PM
📣Update from #ASCO25
Expert insights on the latest data: cor2ed.com/n-connect/pr...
#NSCLC #ProstateCancer #GICancer #BreastCancer #OvarianCancer #CervicalCancer
NSCLC update supported by an Independent Educational Grant from Bayer.Other updates supported by COR2ED
#MedEd @lizzysmyth.bsky.social
Expert insights on the latest data: cor2ed.com/n-connect/pr...
#NSCLC #ProstateCancer #GICancer #BreastCancer #OvarianCancer #CervicalCancer
NSCLC update supported by an Independent Educational Grant from Bayer.Other updates supported by COR2ED
#MedEd @lizzysmyth.bsky.social
📹 Watch the video: cor2ed.com/n-connect/pr...
Video: Recognising #hypophosphatasia (HPP)🔍
- Key manifestations
- Common misdiagnoses
w/ Dr Chad Deal
Programme initiated & funded by Alexion Pharmaceuticals. Intended for healthcare professionals only. GL/UNB-H/0074
#MedEd #EULAR2025
Video: Recognising #hypophosphatasia (HPP)🔍
- Key manifestations
- Common misdiagnoses
w/ Dr Chad Deal
Programme initiated & funded by Alexion Pharmaceuticals. Intended for healthcare professionals only. GL/UNB-H/0074
#MedEd #EULAR2025
Rethinking hypophosphatasia (HPP) diagnosis and disease burden | COR2ED
cor2ed.com
June 12, 2025 at 8:11 AM
📹 Watch the video: cor2ed.com/n-connect/pr...
Video: Recognising #hypophosphatasia (HPP)🔍
- Key manifestations
- Common misdiagnoses
w/ Dr Chad Deal
Programme initiated & funded by Alexion Pharmaceuticals. Intended for healthcare professionals only. GL/UNB-H/0074
#MedEd #EULAR2025
Video: Recognising #hypophosphatasia (HPP)🔍
- Key manifestations
- Common misdiagnoses
w/ Dr Chad Deal
Programme initiated & funded by Alexion Pharmaceuticals. Intended for healthcare professionals only. GL/UNB-H/0074
#MedEd #EULAR2025
📣Highlights from #ESMO Breast Cancer 2025 Satellite Symposium
Experts discuss treatment strategies/sequencing after ET+CDK4/6i for ER+/HER2- metastatic #breastcancer
cor2ed.com/n-connect/pr...
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
Experts discuss treatment strategies/sequencing after ET+CDK4/6i for ER+/HER2- metastatic #breastcancer
cor2ed.com/n-connect/pr...
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
ER+/HER2- metastatic breast cancer: Highlights from ESMO Breast Cancer 2025 Satellite Symposium | COR2ED
In this conference update video, Profs. Wolfgang Janni, Sherko Kümmel and Michail Ignatiadis provide key insights from the highly anticipated ESMO Breast
cor2ed.com
May 26, 2025 at 9:45 AM
📣Highlights from #ESMO Breast Cancer 2025 Satellite Symposium
Experts discuss treatment strategies/sequencing after ET+CDK4/6i for ER+/HER2- metastatic #breastcancer
cor2ed.com/n-connect/pr...
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
Experts discuss treatment strategies/sequencing after ET+CDK4/6i for ER+/HER2- metastatic #breastcancer
cor2ed.com/n-connect/pr...
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
Chemotherapy strategies in mPDAC
➡️How to choose & optimise the different chemotherapeutic options at 1st & 2nd line
w/ Profs. Efrat Dotan & Shubham Pant
📹 Watch the video/listen on Spotify/Apple cor2ed.com/gi-connect/p...
Supported by an Independent Educational Grant from Ipsen USA
#MedEd
➡️How to choose & optimise the different chemotherapeutic options at 1st & 2nd line
w/ Profs. Efrat Dotan & Shubham Pant
📹 Watch the video/listen on Spotify/Apple cor2ed.com/gi-connect/p...
Supported by an Independent Educational Grant from Ipsen USA
#MedEd
Tackling metastatic pancreatic ductal adenocarcinoma (mPDAC) | COR2ED
Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive, with a poor prognosis. It is often diagnosed late, and by this time,
cor2ed.com
May 26, 2025 at 9:41 AM
Chemotherapy strategies in mPDAC
➡️How to choose & optimise the different chemotherapeutic options at 1st & 2nd line
w/ Profs. Efrat Dotan & Shubham Pant
📹 Watch the video/listen on Spotify/Apple cor2ed.com/gi-connect/p...
Supported by an Independent Educational Grant from Ipsen USA
#MedEd
➡️How to choose & optimise the different chemotherapeutic options at 1st & 2nd line
w/ Profs. Efrat Dotan & Shubham Pant
📹 Watch the video/listen on Spotify/Apple cor2ed.com/gi-connect/p...
Supported by an Independent Educational Grant from Ipsen USA
#MedEd
New 2-part animated video series! 🎬
Ep.1 ➡️ 1st line chemotherapy options, key trial data & considering targeted therapy
Ep.2 ➡️ 2nd line chemotherapy options & how earlier treatments impact sequencing
cor2ed.com/gi-connect/p...
Supported by an Independent Educational Grant from Ipsen USA
#MedEd
Ep.1 ➡️ 1st line chemotherapy options, key trial data & considering targeted therapy
Ep.2 ➡️ 2nd line chemotherapy options & how earlier treatments impact sequencing
cor2ed.com/gi-connect/p...
Supported by an Independent Educational Grant from Ipsen USA
#MedEd
Chemotherapy strategies for metastatic pancreatic ductal adenocarcinoma | COR2ED
In this 2-part video animated series, medical oncologists Prof Eileen O’Reilly and Prof Efrat Dotan provide an overview of the different treatment options
cor2ed.com
May 20, 2025 at 7:49 PM
New 2-part animated video series! 🎬
Ep.1 ➡️ 1st line chemotherapy options, key trial data & considering targeted therapy
Ep.2 ➡️ 2nd line chemotherapy options & how earlier treatments impact sequencing
cor2ed.com/gi-connect/p...
Supported by an Independent Educational Grant from Ipsen USA
#MedEd
Ep.1 ➡️ 1st line chemotherapy options, key trial data & considering targeted therapy
Ep.2 ➡️ 2nd line chemotherapy options & how earlier treatments impact sequencing
cor2ed.com/gi-connect/p...
Supported by an Independent Educational Grant from Ipsen USA
#MedEd
🎙️#MedEd podcast
'The #HER2 diagnostic and treatment landscape in #NSCLC'
> Ep. 2: Navigating common treatment scenarios in HER2-mutant NSCLC
➡️w/ @oncbrothers.bsky.social
Watch the video/listen on Spotify/Apple:
cor2ed.com/lung-connect...
Supported by an Independent Educational Grant from Bayer
'The #HER2 diagnostic and treatment landscape in #NSCLC'
> Ep. 2: Navigating common treatment scenarios in HER2-mutant NSCLC
➡️w/ @oncbrothers.bsky.social
Watch the video/listen on Spotify/Apple:
cor2ed.com/lung-connect...
Supported by an Independent Educational Grant from Bayer
The HER2 diagnostic and treatment landscape in NSCLC: Episode 2 | COR2ED
This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in non-small cell lung cancer (NSCLC), hosted by the
cor2ed.com
May 19, 2025 at 4:03 PM
🎙️#MedEd podcast
'The #HER2 diagnostic and treatment landscape in #NSCLC'
> Ep. 2: Navigating common treatment scenarios in HER2-mutant NSCLC
➡️w/ @oncbrothers.bsky.social
Watch the video/listen on Spotify/Apple:
cor2ed.com/lung-connect...
Supported by an Independent Educational Grant from Bayer
'The #HER2 diagnostic and treatment landscape in #NSCLC'
> Ep. 2: Navigating common treatment scenarios in HER2-mutant NSCLC
➡️w/ @oncbrothers.bsky.social
Watch the video/listen on Spotify/Apple:
cor2ed.com/lung-connect...
Supported by an Independent Educational Grant from Bayer
📢 New #lungcancer podcast!
'The #HER2 diagnostic and treatment landscape in #NSCLC'
>> Episode 1: Identifying HER2-directed NSCLC
w/@oncbrothers.bsky.social
Watch the video/listen on Spotify/Apple👇
cor2ed.com/lung-connect...
Supported by an Independent Educational Grant from Bayer
#MedEd
'The #HER2 diagnostic and treatment landscape in #NSCLC'
>> Episode 1: Identifying HER2-directed NSCLC
w/@oncbrothers.bsky.social
Watch the video/listen on Spotify/Apple👇
cor2ed.com/lung-connect...
Supported by an Independent Educational Grant from Bayer
#MedEd
The HER2 diagnostic and treatment landscape in NSCLC: Episode 1 | COR2ED
This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in non-small cell lung cancer (NSCLC), hosted by the
cor2ed.com
May 19, 2025 at 3:56 PM
📢 New #lungcancer podcast!
'The #HER2 diagnostic and treatment landscape in #NSCLC'
>> Episode 1: Identifying HER2-directed NSCLC
w/@oncbrothers.bsky.social
Watch the video/listen on Spotify/Apple👇
cor2ed.com/lung-connect...
Supported by an Independent Educational Grant from Bayer
#MedEd
'The #HER2 diagnostic and treatment landscape in #NSCLC'
>> Episode 1: Identifying HER2-directed NSCLC
w/@oncbrothers.bsky.social
Watch the video/listen on Spotify/Apple👇
cor2ed.com/lung-connect...
Supported by an Independent Educational Grant from Bayer
#MedEd
What do oncology nurses in the USA think about the ways their roles are changing?
GI NURSES CONNECT set out to answer this question in a recent survey 📊
The findings were published in the journal 'Healthcare'
Find out more: cor2ed.com/gi-nurses-co...
Supported by an IME grant from Bayer
#MedEd
GI NURSES CONNECT set out to answer this question in a recent survey 📊
The findings were published in the journal 'Healthcare'
Find out more: cor2ed.com/gi-nurses-co...
Supported by an IME grant from Bayer
#MedEd
Survey on the evolving role of the oncology nurse in the USA | COR2ED
Access the paper online here: The Evolving Role of the Oncology Nurse in the United States of America. The survey results highlight: How roles and
cor2ed.com
May 19, 2025 at 3:43 PM
What do oncology nurses in the USA think about the ways their roles are changing?
GI NURSES CONNECT set out to answer this question in a recent survey 📊
The findings were published in the journal 'Healthcare'
Find out more: cor2ed.com/gi-nurses-co...
Supported by an IME grant from Bayer
#MedEd
GI NURSES CONNECT set out to answer this question in a recent survey 📊
The findings were published in the journal 'Healthcare'
Find out more: cor2ed.com/gi-nurses-co...
Supported by an IME grant from Bayer
#MedEd
HCC micro learning 🎓
The expanding role of immunotherapy in HCC
> Combining locoregional & systemic treatments in intermediate HCC
Video, slides, flashcard + accredited assessment
👉 cor2ed.com/hcc-connect/...
AstraZeneca has provided a sponsorship grant towards this independent programme
#MedEd
The expanding role of immunotherapy in HCC
> Combining locoregional & systemic treatments in intermediate HCC
Video, slides, flashcard + accredited assessment
👉 cor2ed.com/hcc-connect/...
AstraZeneca has provided a sponsorship grant towards this independent programme
#MedEd
The expanding role of immunotherapy in HCC | COR2ED
In this micro learning developed by experts Prof. Aiwu Ruth He and Prof. Beau Toskich, you’ll learn about the expanding role of immunotherapy (IO) in
cor2ed.com
May 19, 2025 at 3:36 PM
HCC micro learning 🎓
The expanding role of immunotherapy in HCC
> Combining locoregional & systemic treatments in intermediate HCC
Video, slides, flashcard + accredited assessment
👉 cor2ed.com/hcc-connect/...
AstraZeneca has provided a sponsorship grant towards this independent programme
#MedEd
The expanding role of immunotherapy in HCC
> Combining locoregional & systemic treatments in intermediate HCC
Video, slides, flashcard + accredited assessment
👉 cor2ed.com/hcc-connect/...
AstraZeneca has provided a sponsorship grant towards this independent programme
#MedEd